BR112022013488A2 - Pirazolo-pirimidinas substituídas e seu uso - Google Patents

Pirazolo-pirimidinas substituídas e seu uso

Info

Publication number
BR112022013488A2
BR112022013488A2 BR112022013488A BR112022013488A BR112022013488A2 BR 112022013488 A2 BR112022013488 A2 BR 112022013488A2 BR 112022013488 A BR112022013488 A BR 112022013488A BR 112022013488 A BR112022013488 A BR 112022013488A BR 112022013488 A2 BR112022013488 A2 BR 112022013488A2
Authority
BR
Brazil
Prior art keywords
pyrimidines
substituted pyrazolo
compounds
treatment
pikfyve
Prior art date
Application number
BR112022013488A
Other languages
English (en)
Inventor
D Rosen Mark
A Galemmo Robert Jr
Liang Weiling
Y Choi Irene
Kopek Brian
Rhodes Jane
Original Assignee
Verge Analytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verge Analytics Inc filed Critical Verge Analytics Inc
Publication of BR112022013488A2 publication Critical patent/BR112022013488A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

PIRAZOLO-PIRIMIDINAS SUBSTITUÍDAS E SEU USO. A presente invenção refere-se a compostos que são inibidores das PIKfyve cinases úteis para o tratamento de doenças neurológicas tratáveis através da inibição de PIKfyve. Também são fornecidas composições farmacêuticas contendo tais compostos e métodos de tratamento utilizando tais compostos.
BR112022013488A 2020-01-13 2021-01-12 Pirazolo-pirimidinas substituídas e seu uso BR112022013488A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062960412P 2020-01-13 2020-01-13
US202063074388P 2020-09-03 2020-09-03
PCT/US2021/013077 WO2021146192A1 (en) 2020-01-13 2021-01-12 Substituted pyrazolo-pyrimidines and uses thereof

Publications (1)

Publication Number Publication Date
BR112022013488A2 true BR112022013488A2 (pt) 2022-09-13

Family

ID=74626126

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013488A BR112022013488A2 (pt) 2020-01-13 2021-01-12 Pirazolo-pirimidinas substituídas e seu uso

Country Status (14)

Country Link
US (1) US20230133203A1 (pt)
EP (1) EP4090426A1 (pt)
JP (1) JP2023510874A (pt)
KR (1) KR20220140515A (pt)
CN (1) CN115209952A (pt)
AU (1) AU2021207804A1 (pt)
BR (1) BR112022013488A2 (pt)
CA (1) CA3167339A1 (pt)
CL (1) CL2022001887A1 (pt)
CO (1) CO2022011258A2 (pt)
IL (1) IL294504A (pt)
MX (1) MX2022008627A (pt)
TW (1) TW202140483A (pt)
WO (1) WO2021146192A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202313619A (zh) * 2021-06-01 2023-04-01 美商邊際分析公司 稠合雙環雜環化合物及其用途
WO2024014885A1 (ko) * 2022-07-13 2024-01-18 일동제약(주) 신규 바이사이클릭 헤테로아릴 화합물 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
WO2016210372A2 (en) 2015-06-25 2016-12-29 University Of Southern California Methods to treat neurological diseases
WO2018175906A1 (en) * 2017-03-24 2018-09-27 Nanosyn, Inc. Fused triazolo-pyrimidine compounds having useful pharmaceutical application
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. PIKFYVE KINASE INHIBITORS
KR20210029790A (ko) * 2018-07-05 2021-03-16 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 PIKfyve 저해제

Also Published As

Publication number Publication date
JP2023510874A (ja) 2023-03-15
US20230133203A1 (en) 2023-05-04
CA3167339A1 (en) 2021-07-22
CL2022001887A1 (es) 2023-04-10
CN115209952A (zh) 2022-10-18
KR20220140515A (ko) 2022-10-18
AU2021207804A1 (en) 2022-09-01
TW202140483A (zh) 2021-11-01
MX2022008627A (es) 2022-11-08
IL294504A (en) 2022-09-01
WO2021146192A1 (en) 2021-07-22
CO2022011258A2 (es) 2022-09-30
EP4090426A1 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
BR112022000064A2 (pt) Inibidores de hpk1 e usos dos mesmos
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
BR112021020637A2 (pt) Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
BR112015015635A8 (pt) composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
BR112019018648A2 (pt) Inibidores de jak contendo uma amida heterocíclica com 4 membros
BR112015021999A8 (pt) inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BR112012010705A2 (pt) composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio
BR112021023824A8 (pt) Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica
CO2022011258A2 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
CL2022003329A1 (es) Derivados de tetrazol como inhibidores de trpa1
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
BR112023015425A2 (pt) Derivados de uracila como inibidores de trpa1
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
DOP2022000270A (es) Derivados de tetrazol como inhibidores de trpa1
CO2023000858A2 (es) Inhibidores de atr y usos de estos
CL2021000282A1 (es) Inhibidores de ckd8/19
UY38133A (es) Nuevos inhibidores de cdk8/19